This page shows the latest Abivax news and features for those working in and with pharma, biotech and healthcare.
Abivax is devoting significant efforts to this major international clinical trial and simultaneously accelerating ABX464 manufacturing scale-up for potential 2021 commercialisation,” he added. ... In July, Abivax treated the first patient in the phase
French biotech company Abivax is also currently investigating its experimental ulcerative colitis drug ABX464 as an early treatment for elderly or high-risk patients with COVID-19.
Another anti-inflammatory drug, ABX464, is currently being studied by Abivax as an early treatment for elderly or high-risk patients with confirmed COVID-19.
A host of candidates are being investigated to regulate the overactive inflammatory side effects associated with some cases of COVID-19, including Abivax’s experimental anti-inflammatory med ABX464. ... Last week, Abivax initiated a phase 2b/3 study
Study will evaluate experimental anti-inflammatory drug. French biotech company Abivax has treated the first patient in a phase 2b/3 study of its experimental anti-inflammatory drug ABX464 in ... Currently, Abivax has received approval for studies in
The drug reduced HIV DNA in cells over 28 days. French biotech Abivax has new data for its HIV drug candidate ABX464 that suggest it may suppress latent HIV in reservoirs – ... Those anti-inflammatory properties have encouraged Abivax to carry out a
More from news
Approximately 3 fully matching, plus 4 partially matching documents found.
Another company working on a similar candidate is French biotech Abivax.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Graphite is a digital agency which partners with globally respected pharma and healthcare organisations to create powerful digital experiences. We...